

ASX ANNOUNCEMENT 27 June 2024

Disclosure of Media Statements

EZZ Life Science Holdings Limited (ASX: EZZ) ("EZZ" or the "Company") wishes to disclose to the market statements made during a recent media interview. On 26 June 2024, the Company's Chair, Mr Glenn Cross, was interviewed by AusBiz regarding EZZ's recent company developments.

During this interview, Mr Cross mentioned that EZZ has approximately A\$19 million in cash. The Company would like to fully disclose that EZZ anticipates having approximately A\$19 million (unaudited) in cash by the end of the fourth quarter of FY24.

EZZ will release its quarterly results for the fourth quarter in July 2024, which will provide a comprehensive update on the Company's financial position, including the cash balance.

The Company remains committed to keeping the market informed and will provide further updates as necessary.

This announcement has been authorised by the Board of EZZ Life Science Holdings Limited.

ENDS

For further information, please contact:

Investors

https://www.ezzlife.com.au/investors ir@ezzlife.com.au

Media

James Hudson +61 467 761 166 james.hudson@ezzlife.com.au

About EZZ Life Science

EZZ Life Science Holdings Limited (ASX:EZZ) is an Australian genomic life science company with a mission to improve quality of life and human health. EZZ Life Science has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), children's health, and weight management. EZZ Life Science is passionate about investing in the future of consumer health through the development of e-commerce and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide. EZZ Life Science is led by an experienced senior management team that have implemented strategies to drive rapid and ongoing growth of the business.

For more information please visit our corporate site ezzlife.com.au and our consumer site ezzdna.com.au.